Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Milletti

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Nature Medicine|March 22, 2022
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trialSattva S Neelapu, Michael Dickinson, Javier Munoz, et al.
Blood Advances|July 20, 2022
Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapiesArmin Ghobadi, Jack H Landmann, Alun Carter, et al.
Science Advances|May 23, 2020
Inhibition of IRF5 cellular activity with cell-penetrating peptides that target homodimerizationJaspreet Banga, Dinesh Srinivasan, Chia-Chi Sun, et al.
Lancet (London, England)|June 7, 2021
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Nature Medicine|March 22, 2022
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trialSattva S Neelapu, Michael Dickinson, Javier Munoz, et al.
Blood Advances|July 20, 2022
Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapiesArmin Ghobadi, Jack H Landmann, Alun Carter, et al.
Science Advances|May 23, 2020
Inhibition of IRF5 cellular activity with cell-penetrating peptides that target homodimerizationJaspreet Banga, Dinesh Srinivasan, Chia-Chi Sun, et al.
Lancet (London, England)|June 7, 2021
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Pageof 3